Nu Med Plus Stock Performance

NUMD Stock  USD 0.05  0  5.40%   
On a scale of 0 to 100, Nu Med holds a performance score of 3. The company owns a Beta (Systematic Risk) of -1.54, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Nu Med are expected to decrease by larger amounts. On the other hand, during market turmoil, Nu Med is expected to outperform it. Please check Nu Med's information ratio and the relationship between the maximum drawdown and price action indicator , to make a quick decision on whether Nu Med's current price history will revert.

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Nu Med Plus are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady primary indicators, Nu Med exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow188.5 K
Free Cash Flow-206.8 K
  

Nu Med Relative Risk vs. Return Landscape

If you would invest  5.00  in Nu Med Plus on April 23, 2025 and sell it today you would earn a total of  0.00  from holding Nu Med Plus or generate 0.0% return on investment over 90 days. Nu Med Plus is currently generating 0.322% in daily expected returns and assumes 8.1279% risk (volatility on return distribution) over the 90 days horizon. In different words, 72% of otc stocks are less volatile than NUMD, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Nu Med is expected to generate 10.49 times more return on investment than the market. However, the company is 10.49 times more volatile than its market benchmark. It trades about 0.04 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.25 per unit of risk.

Nu Med Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Nu Med's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Nu Med Plus, and traders can use it to determine the average amount a Nu Med's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0396

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsNUMD
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 8.13
  actual daily
72
72% of assets are less volatile

Expected Return

 0.32
  actual daily
6
94% of assets have higher returns

Risk-Adjusted Return

 0.04
  actual daily
3
97% of assets perform better
Based on monthly moving average Nu Med is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nu Med by adding it to a well-diversified portfolio.

Nu Med Fundamentals Growth

NUMD OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Nu Med, and Nu Med fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NUMD OTC Stock performance.

About Nu Med Performance

By analyzing Nu Med's fundamental ratios, stakeholders can gain valuable insights into Nu Med's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nu Med has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nu Med has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people.

Things to note about Nu Med Plus performance evaluation

Checking the ongoing alerts about Nu Med for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Nu Med Plus help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Nu Med Plus had very high historical volatility over the last 90 days
Nu Med Plus has some characteristics of a very speculative penny stock
Nu Med Plus currently holds 2.06 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Nu Med Plus has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nu Med until it has trouble settling it off, either with new capital or with free cash flow. So, Nu Med's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Med Plus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NUMD to invest in growth at high rates of return. When we think about Nu Med's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (830.06 K) with profit before overhead, payroll, taxes, and interest of 0.
Nu Med Plus currently holds about 2.54 K in cash with (206.83 K) of positive cash flow from operations.
Roughly 62.0% of Nu Med outstanding shares are owned by corporate insiders
Evaluating Nu Med's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Nu Med's otc stock performance include:
  • Analyzing Nu Med's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nu Med's stock is overvalued or undervalued compared to its peers.
  • Examining Nu Med's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Nu Med's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nu Med's management team can help you assess the OTC Stock's leadership.
  • Pay attention to analyst opinions and ratings of Nu Med's otc stock. These opinions can provide insight into Nu Med's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Nu Med's otc stock performance is not an exact science, and many factors can impact Nu Med's otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for NUMD OTC Stock analysis

When running Nu Med's price analysis, check to measure Nu Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nu Med is operating at the current time. Most of Nu Med's value examination focuses on studying past and present price action to predict the probability of Nu Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nu Med's price. Additionally, you may evaluate how the addition of Nu Med to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Money Managers
Screen money managers from public funds and ETFs managed around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules